Page last updated: 2024-09-02

quinaprilat and rxp 407

quinaprilat has been researched along with rxp 407 in 2 studies

Compound Research Comparison

Studies
(quinaprilat)
Trials
(quinaprilat)
Recent Studies (post-2010)
(quinaprilat)
Studies
(rxp 407)
Trials
(rxp 407)
Recent Studies (post-2010) (rxp 407)
922341504

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Batenburg, WW; Danser, AH; de Bruijn, RJ; de Vries, R; Dive, V; Georgiadis, D; Tom, B; van Esch, JH; van Gool, JM; Yiotakis, A1
de Bruin, RJ; Deinum, J; Dive, V; Hectors, M; Jan Danser, AH; Montgomery, HE; Payne, JR; van Esch, JH; van Gool, JM1

Other Studies

2 other study(ies) available for quinaprilat and rxp 407

ArticleYear
Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Captopril; Coronary Vessels; Dose-Response Relationship, Drug; Female; Femoral Artery; Humans; Male; Microcirculation; Middle Aged; Oligopeptides; Organ Specificity; Peptidyl-Dipeptidase A; Phosphinic Acids; Protein Structure, Tertiary; Solubility; Structure-Activity Relationship; Sus scrofa; Tetrahydroisoquinolines; Vasoconstriction

2005
Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype.
    Journal of hypertension, 2008, Volume: 26, Issue:4

    Topics: Adult; Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Coronary Vessels; Enzyme Activation; Female; Genotype; Humans; In Vitro Techniques; Male; Middle Aged; Oligopeptides; Peptidyl-Dipeptidase A; Phosphinic Acids; Point Mutation; Protein Structure, Tertiary; Sus scrofa; Tetrahydroisoquinolines; Vasoconstrictor Agents; Vasodilator Agents

2008